YH004, a potential therapeutic for advanced solid tumors and relapsed/refractory non-Hodgkin’s lymphoma (r/r NHL), is currently undergoing a phase I dose escalation study in Australia as monotherapy. The study was approved under the CTN scheme by the Australian Therapeutic Goods Administration (TGA) in June 2021 and we have completed the dosing of the first patient in December 2021. As of December 31, 2022, 8 subjects were enrolled and received 0.01 mg/kg (n=1), 0.03 mg/kg (n=1), 0.1 mg/kg (n=3), and 0.3 mg/kg (n=3) dosing. 2 subjects had a best efficacy assessment of SD. All adverse events associated with YH004 were mild or moderate (Grade 1 or 2).Trial #：YH004002
We have also received IND approval from the U.S. FDA in October 2021.
We have received the approval for the IND applications by the NMPA on January 7, 2022.
4-1BB is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and is expressed in activated T cells within the tumor microenvironment. Antibody-mediated stimulation of 4-1BB can enhance the release of CD8+ T cell effectors through costimulatory signals, promote cell proliferation while inhibiting apoptosis, and ultimately improve the anti-tumor immune response.
Bristol-Myers Squibb's urelumab (BMS-663513) is the first therapeutic drug targeting 4-1BB that has entered clinical trials. However, there are currently no 4-1BB drugs on the market.